Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A device profile of the SynCardia temporary total artificial heart as a bridge-to-transplantation in patients with biventricular failure.

Expert review of medical devices·2025

Same author

TEG® 6s-Guided Algorithm for Optimizing Patient Blood Management in Cardiovascular Surgery: Systematic Literature Review and Expert Opinion.

Journal of cardiothoracic and vascular anesthesia·2025

Same author

Fair and Just Opportunity: Streamlining COVID-19 Extracorporeal Membrane Oxygenation Referrals on a Statewide Platform to Enhance Equity.

Annals of the American Thoracic Society·2024

Same author

Blood Volume Analysis of Total Artificial Heart Recipients: A Case Series.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2024

Same author

In Search of the Holy Grail of Artificial Hearts: Are We There Yet?

Seminars in thrombosis and hemostasis·2023

Same author

The total artificial heart: where have we been, where are we now, where are we going?

Indian journal of thoracic and cardiovascular surgery·2023

Search research articles

Related Experiment Video

Updated: Dec 19, 2025

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

The Total Artificial Heart: Where Are We?

Francisco A Arabía^1,2

¹From the Departments of Surgery.

Cardiology in Review

|June 6, 2020

Summary

The total artificial heart (TAH) offers a bridge to transplantation for severe heart failure patients. Experienced centers report 73% 1-year survival, with outcomes dependent on patient selection and care.

Area of Science:

Cardiology
Biomedical Engineering
Mechanical Circulatory Support

Background:

The total artificial heart (TAH) replaces failing ventricles, offering a lifeline for end-stage heart failure.
The SynCardia temporary TAH is the most widely used device, approved for bridging patients to heart transplantation.
Indications include severe biventricular failure or conditions unsuitable for left ventricular assist devices.

Purpose of the Study:

To review the current status and patient outcomes associated with the SynCardia temporary TAH.
To identify risk factors and common causes of mortality in TAH recipients.
To provide an overview of emerging TAH technologies.

Main Methods:

Review of patient data and outcomes from experienced centers with TAH implantation.

More Related Videos

Implantation of the Syncardia Total Artificial Heart

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Implantation of Total Artificial Heart in Congenital Heart Disease

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Related Experiment Videos

Last Updated: Dec 19, 2025

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Implantation of the Syncardia Total Artificial Heart

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Implantation of Total Artificial Heart in Congenital Heart Disease

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Analysis of survival rates, risk factors for mortality, and common causes of death.

Discussion of patient selection criteria, device management, and emerging TAH designs.

Main Results:

The SynCardia temporary TAH has the largest patient experience, with 50-mL and 70-mL versions approved.
One-year survival in experienced centers (implanting >10 TAHs) is 73%.
Risk factors for mortality include older age, need for dialysis, and malnutrition; common causes are organ failure and neurologic dysfunction.

Conclusions:

The TAH enables outpatient management, but successful outcomes depend on careful patient selection, timely intervention, and comprehensive care.
Emerging TAH technologies like CARMAT and BiVACOR TAH show promise for future clinical applications.
Continued research and development in TAH technology are crucial for improving patient survival and quality of life.